Digestive System Diseases

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : Digestive System Diseases

Top of Directory » All Categories » by Illness » Digestive System Diseases



  • Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer

    Conditions:   Stomach Cancer;   Gall Bladder Cancer;   Bile Ductus Cancer;   Pancreas Cancer;   Colorectal Cancer
    Intervention:   Other: oxaliplatin, capecitabine, radiotherapy
    Sponsors:   Lund University Hospital;   Roche Pharma AG;   Sanofi-Synthelabo
    Completed - verified November 2009
  • A Study of OSI-906 and Irinotecan in Patients With Advanced Cancer With Expanded Cohorts of Patients With KRAS Mutant Colorectal Cancer

    Condition:   Colorectal Cancer
    Intervention:   Drug: Treatment with OSI-906 and/or irinotecan
    Sponsor:   University of Colorado at Denver and Health Sciences Center
    Not yet recruiting - verified November 2009
  • Chemotherapy-Induced Peripheral Neuropathy Survey

    Conditions:   Breast Cancer;   Colorectal Cancer;   Myeloma;   Chemotherapy-Induced Peripheral Neuropathy
    Interventions:   Behavioral: Questionnaire;   Behavioral: Sensory Tests;   Behavioral: Interview
    Sponsor:   M.D. Anderson Cancer Center
    Not yet recruiting - verified November 2009
  • Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

    Condition:   Advanced Gastric Cancer
    Interventions:   Drug: Paclitaxel;   Drug: capecitabine;   Drug: capecitabine;   Drug: cisplatin
    Sponsors:   Peking University;   Roche Pharma AG
    Recruiting - verified November 2009
  • Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

    Condition:   Liver Cancer
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: sorafenib tosylate
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma

    Condition:   Non-curative Resectable Bile Duct Carcinoma
    Intervention:   Drug: Temoporfin
    Sponsors:   University of Salzburg;   Biolitec Pharma ltd., United Drug House, Magna Drive,Dublin 24,Irland
    Recruiting - verified November 2009
  • Erlotinib Hydrochloride in Treating Patients With Previously Treated Non-Small Cell Lung Cancer, Head and Neck Cancer, or Esophageal Cancer and Precancerous Lesions of the Lung

    Conditions:   Cancer Survivor;   Esophageal Cancer;   Head and Neck Cancer;   Lung Cancer;   Precancerous/Nonmalignant Condition
    Interventions:   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
    Sponsors:   Robert H. Lurie Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Telemark Polyp Study, a Trial on Colonoscopy Screening

    Condition:   Colorectal Cancer
    Intervention:   Procedure: endoscopy
    Sponsor:   Norwegian Department of Health and Social Affairs
    Active, not recruiting - verified November 2009
  • Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

    Conditions:   Breast Cancer;   Lung Cancer;   Colon Cancer;   Pancreatic Cancer;   Head and Neck Cancer;   Kidney Cancer;   Sarcoma;   Hepatocellular Cancer
    Interventions:   Drug: Pazopanib;   Drug: Pazopanib;   Drug: Ixabepilone;   Drug: Ixabepilone;   Drug: Ixabepilone
    Sponsors:   Masonic Cancer Center, University of Minnesota;   GlaxoSmithKline;   Bristol-Myers Squibb
    Recruiting - verified November 2009
  • Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer

    Condition:   Colorectal Cancer
    Interventions:   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
    Sponsors:   Lombardi Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By Chemotherapy With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

    Condition:   Pancreatic Cancer
    Interventions:   Drug: capecitabine;   Drug: erlotinib hydrochloride;   Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

    Conditions:   Colorectal Cancer;   Precancerous/Nonmalignant Condition
    Interventions:   Drug: rosuvastatin;   Other: placebo
    Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Interventions:   Procedure: Endoscopic Ultrasound (EUS);   Device: EUS/4D-ELF
    Sponsor:   Mayo Clinic
    Not yet recruiting - verified November 2009
  • Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor

    Conditions:   Endometrial Cancer;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Liver Cancer;   Lung Cancer;   Ovarian Cancer
    Interventions:   Biological: bevacizumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Temsirolimus and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer and Liver Dysfunction

    Conditions:   Hepatic Complications;   Liver Cancer
    Interventions:   Drug: sorafenib tosylate;   Drug: temsirolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   UCSF Helen Diller Family Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • ABT-888 and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

    Conditions:   Ovarian Cancer;   Peritoneal Cavity Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: ABT-888;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Regulatory Post Marketing Surveillance Study on Nexavar®

    Conditions:   Carcinoma, Hepatocellular;   Carcinoma, Renal Cell
    Intervention:   Drug: Sorafenib ( Nexavar, BAY43-9006)
    Sponsor:   Bayer
    Recruiting - verified November 2009
  • Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

    Condition:   Liver Cancer
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: mitomycin C;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

    Conditions:   Ovarian Neoplasms;   Peritoneal Neoplasms
    Interventions:   Drug: BIBF 1120;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Not yet recruiting - verified November 2009
  • Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

    Condition:   Advanced Pancreatic Cancer
    Interventions:   Drug: erlotinib;   Drug: Gemcitabine;   Drug: Nab-paclitaxel
    Sponsor:   OSI Pharmaceuticals
    Not yet recruiting - verified November 2009
  • Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

    Condition:   Liver Cancer
    Interventions:   Drug: doxorubicin-eluting beads;   Drug: everolimus;   Other: placebo
    Sponsor:   Swiss Group for Clinical Cancer Research
    Not yet recruiting - verified November 2009
  • Multipolar Radiofrequency Ablation for Hepatocellular Carcinoma Using Extra Nodular Versus Intranodular Technique

    Condition:   Hepatocellular Carcinomas
    Intervention:   Procedure: Radiofrequency ablation
    Sponsor:   Assistance Publique - Hôpitaux de Paris
    Not yet recruiting - verified November 2009
  • Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

    Condition:   Liver Cancer
    Interventions:   Biological: cixutumumab;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
    Sponsors:   California Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma

    Conditions:   Hepatocellular Carcinoma;   Hepatitis C Virus Chronic Infection
    Intervention:   Biological: CP 675,206
    Sponsors:   Instituto Cientifico y Tecnologico de Navarra, Universidad de Navarra;   Pfizer
    Recruiting - verified November 2009
  • A Phase II Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts

    Condition:   Adenocarcinoma of Gall Bladder or Biliary Ducts
    Intervention:   Drug: Gemcitabine, Capecitabine and Bevacizumab
    Sponsor:   Roswell Park Cancer Institute
    Not yet recruiting - verified November 2009
  • Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

    Condition:   Colorectal Cancer
    Interventions:   Biological: bevacizumab;   Drug: XELOX regimen;   Drug: capecitabine;   Drug: hydroxychloroquine;   Drug: oxaliplatin;   Other: laboratory biomarker analysis
    Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
    Recruiting - verified August 2009
  • Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma

    Conditions:   Chronic Hepatitis C;   Neoplasms
    Intervention:   Drug: Peginterferon alfa-2a plus ribavirn
    Sponsor:   Kaohsiung Medical University
    Active, not recruiting - verified November 2009
  • A Study of Erlotinib in Patients With Premalignant Lung Lesions

    Conditions:   Lung Cancer;   Esophageal Cancer;   Head and Neck Cancer
    Intervention:   Drug: Erlotinib
    Sponsors:   Roswell Park Cancer Institute;   Northwestern University;   National Cancer Institute (NCI)
    Not yet recruiting - verified October 2009
  • Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan

    Condition:   Colorectal Cancer
    Intervention:   Drug: cetuximab with irinotecan
    Sponsor:   Roswell Park Cancer Institute
    Recruiting - verified May 2009
  • Colorectal Cancer Survivors' Needs and Preferences for Survivorship Information

    Conditions:   Colon Cancer;   Rectal Cancer
    Intervention:   Behavioral: Questionnaire
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Queens Cancer Center
    Enrolling by invitation - verified October 2009
  • Genetic Investigation of Solid Tumors Cohort

    Conditions:   Prostate Cancer;   Colon Cancer
    Intervention:  
    Sponsor:   Scripps Translational Science Institute
    Recruiting - verified October 2009
  • Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma

    Conditions:   Hepatocellular Carcinoma;   Liver Cancer
    Interventions:   Drug: Sorafenib;   Radiation: Stereotactic Body Radiotherapy (SBRT)
    Sponsors:   University of Alabama at Birmingham;   Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
    Not yet recruiting - verified November 2009
  • Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

    Condition:   Hepatocellular Carcinoma
    Intervention:   Drug: sorafenib with temsirolimus
    Sponsors:   University of California, San Francisco;   Northwestern University
    Not yet recruiting - verified November 2009
  • Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer

    Condition:   Liver Cancer
    Interventions:   Drug: everolimus;   Drug: sorafenib tosylate;   Other: questionnaire administration;   Procedure: quality-of-life assessment
    Sponsor:   Swiss Group for Clinical Cancer Research
    Not yet recruiting - verified November 2009
  • Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

    Condition:   Liver Cancer
    Interventions:   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: mitomycin C;   Drug: sorafenib tosylate;   Other: placebo
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • SprayShield EU Post Market Study

    Conditions:   Ulcerative Colitis;   Familial Polyposis
    Interventions:   Device: SprayShield Adhesion Barrier System;   Procedure: Good Surgical Technique Alone
    Sponsor:   Confluent Surgical
    Recruiting - verified October 2009
  • Efficacy Study of Helicobacter Pylori Eradication in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer

    Condition:   Gastric Cancer
    Interventions:   Drug: Helicobacter pylori eradication;   Drug: placebo
    Sponsor:   National Cancer Center, Korea
    Completed - verified October 2009
  • ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer

    Condition:   Metastatic Colorectal Cancer
    Interventions:   Drug: Cetuximab (Erbitux);   Drug: Panitumumab (Vectibix)
    Sponsor:   Amgen
    Not yet recruiting - verified November 2009
  • Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer

    Condition:   Hepatocellular Carcinoma
    Intervention:   Drug: Sorafenib
    Sponsor:   Fudan University
    Recruiting - verified October 2009
    • Menu
    Find Paid Clinical Trials